Neurosarcoidosis : Initial Presentation and Disease Course
NEUROSARC
1 other identifier
observational
80
1 country
1
Brief Summary
Neurosarcoidosis represents up to 10% of sarcoidosis cases. Little is known about its long-term course, even if the disease remains mainly monophasic with/w.o. sequelae, or if bouts of new symptoms may arise over years (polyphasic). Using retrospective data from patients diagnosed with neurosarcoidosis in three French referral centers for neuro-inflammation, the investigators aim to determine patterns of disease course, according to the initial presentation and the treatments used.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jun 2021
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 18, 2021
CompletedStudy Start
First participant enrolled
June 1, 2021
CompletedFirst Posted
Study publicly available on registry
June 3, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2021
CompletedJune 3, 2021
February 1, 2021
2 months
February 18, 2021
May 27, 2021
Conditions
Outcome Measures
Primary Outcomes (1)
change in disease characteristics from Baseline to end of study
composite variable with three categories : monophasic course / polyphasic course with the same symptoms / polyphasic course with different symptoms This variable is composite and its evaluated by the investigators by reviewing the medical file with every available document : MRI results, clinical evaluation
from baseline to end of study (an average of 6 years)
Interventions
no intervention
Eligibility Criteria
Every patient of the three centers meeting the inclusion criteria
You may qualify if:
- To have at least one documented visit in one of the three referral neurological centers (Nancy, Bordeaux, Strasbourg) between Jan-1st-2000 and Jan-1st-2021
- To be diagnosed with possible/probable/definite neurosarcoidosis
You may not qualify if:
- \- Denial to participate to the study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Guillaume Mathey
Nancy, Lorraine, 54000, France
MeSH Terms
Conditions
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 18, 2021
First Posted
June 3, 2021
Study Start
June 1, 2021
Primary Completion
August 1, 2021
Study Completion
August 1, 2021
Last Updated
June 3, 2021
Record last verified: 2021-02
Data Sharing
- IPD Sharing
- Will not share